Literature DB >> 11117546

Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.

C Bjartmar1, G Kidd, S Mörk, R Rudick, B D Trapp.   

Abstract

Axonal degeneration has been proposed as a cause of irreversible neurological disability in multiple sclerosis (MS) patients. The purpose of this study was to quantify axonal loss in spinal cord lesions from 5 paralyzed (Expanded Disability Status Scale score > or =7.5) MS patients and to determine if axonal number or volume correlated with levels of the neuronal marker N-acetyl aspartate (NAA). Axonal loss in MS lesions ranged from 45 to 84% and averaged 68%. NAA levels were significantly reduced (>50%) in cross sections of spinal cords containing MS lesions. Reduced NAA correlated with reduced axonal numbers within lesion areas. In addition, NAA levels per axonal volume were significantly reduced in demyelinated axons (42%) and in myelinated axons in normal-appearing white matter (30%). The data support axonal loss as a major cause of irreversible neurological disability in paralyzed MS patients and indicate that reduced NAA as measured by magnetic resonance spectroscopy can reflect axonal loss and reduced NAA levels in demyelinated and myelinated axons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117546

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  153 in total

Review 1.  Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.

Authors:  Massimo Filippi; Maria A Rocca; Marco Rovaris
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

2.  14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis.

Authors:  Jérôme de Seze; Katel Peoc'h; Didier Ferriby; Tanya Stojkovic; Jean-Louis Laplanche; Patrick Vermersch
Journal:  J Neurol       Date:  2002-05       Impact factor: 4.849

3.  Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel In Vivo MR Method for Measuring Myelin, Axons, and G-Ratio.

Authors:  A Hagiwara; M Hori; K Yokoyama; M Nakazawa; R Ueda; M Horita; C Andica; O Abe; S Aoki
Journal:  AJNR Am J Neuroradiol       Date:  2017-08-03       Impact factor: 3.825

4.  MR spectroscopy of cervical spinal cord in patients with multiple sclerosis.

Authors:  Ayşe Tuba Karagülle Kendi; Funda Uysal Tan; Mustafa Kendi; Sevda Yilmaz; Sinef Huvaj; Serdar Tellioğlu
Journal:  Neuroradiology       Date:  2004-09       Impact factor: 2.804

Review 5.  Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials.

Authors:  Frederik Barkhof
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 6.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

7.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.

Authors:  J M Stankiewicz; M Neema; D C Alsop; B C Healy; A Arora; G J Buckle; T Chitnis; C R G Guttmann; D Hackney; R Bakshi
Journal:  J Neurol Sci       Date:  2009-04-15       Impact factor: 3.181

Review 8.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

9.  2D phase-sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times.

Authors:  Nico Papinutto; Regina Schlaeger; Valentina Panara; Eduardo Caverzasi; Sinyeob Ahn; Kevin J Johnson; Alyssa H Zhu; William A Stern; Gerhard Laub; Stephen L Hauser; Roland G Henry
Journal:  J Magn Reson Imaging       Date:  2014-12-08       Impact factor: 4.813

10.  Axonal degeneration and progressive neurologic disability in multiple sclerosis.

Authors:  Carl Bjartmar; Bruce D Trapp
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.